Abstract 825: Correlation of clinical and biomarker data in FGFR inhibitor failed metastatic cholangiocarcinoma patients with tumor response to tinengotinib
Sign Up to like & getrecommendations! Published in 2025 at "Cancer Research"
DOI: 10.1158/1538-7445.am2025-825
Abstract: Cholangiocarcinoma (CCA) patients (pts) harboring FGFR fusions treated with FGFR inhibitors (FGFRi) have shown clinical benefit, but often have progression in 5- 7 months. Secondary polyclonal mutations in the FGFR2 kinase domain (KD) may be… read more here.
Keywords: response; cca pts; biomarker data; tinengotinib ... See more keywords
A phase 1b/2 study evaluating the activity of tinengotinib in combination with androgen receptor pathway inhibitors (ARPIs) in patients with metastatic castration resistant prostate cancer (mCRPC).
Sign Up to like & getrecommendations! Published in 2025 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2025.43.5_suppl.tps290
Abstract: TPS290 Background: Androgen receptor pathway inhibitors (ARPIs) are standard life-prolonging therapies for patients with metastatic castration-resistant prostate cancer (mCRPC), but patients ultimately progress on these agents. Resistance has been shown to occur in part via… read more here.
Keywords: receptor; prednisone enzalutamide; prostate cancer; tinengotinib ... See more keywords